Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature.

Expert opinion on therapeutic patents - 1 Dec 2021

Thompson Severin K, Buckl Andreas, Dossetter Alexander G, Griffen Ed, Gill Adrian

Abstract excerpt

Introduction: Up to 30% of all human cancers are driven by the overactivation of RAS signaling. Son of Sevenless 1 (SOS1) is a central node in RAS signaling pathways and modulation of SOS1-mediated RAS activation represents a unique opportunity for treating RAS-addicted cancers. Several recent publications and patent documents have demonstrated the ability of small molecules to affect the activation of RAS by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Drug Development

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Neoplasms

Share to Patents as Topic

Share to ras Proteins

Share to Signal Transduction

Share to SOS1 Protein

Source

Identifiers

PMID: 34253125
DOI: 10.1080/13543776.2021.1952984

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature.PMID 34253125Read ↗

Targeting Son of Sevenless 1: The pacemaker of KRAS.Semantic proximity Read ↗

SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers.Semantic proximity Read ↗

SOS1-inspired hydrocarbon-stapled peptide as a pan-Ras inhibitor.Semantic proximity Read ↗

Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations.Semantic proximity Read ↗

Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices.Semantic proximity Read ↗

Cereblon-based Bifunctional Degrader of SOS1, BTX-6654, Targets Multiple KRAS Mutations and Inhibits Tumor Growth.Semantic proximity Read ↗

Discovery of novel indazole derivatives as SOS1 agonists that activate KRAS signaling.Semantic proximity Read ↗

Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR.Semantic proximity Read ↗

Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia.Semantic proximity Read ↗

The SOS1 Inhibitor BI 1701963 as Monotherapy or in Combination with Trametinib in Patients with KRAS Mutation-Positive Solid Tumors.Semantic proximity Read ↗

The translational role of SOS1 in colorectal cancerSemantic proximity Read ↗

Development of SOS1 Inhibitor-Based Degraders to Target KRAS-Mutant Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.